SCHEMBL16587775

SCHEMBL16587775

Cc1ccc(N2CCC(C(C)(C)C)C(C)(C)C2)nn1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OGA O60502 1/20 0.33
PTGES O14684 2/20 0.32
NR1I2 O75469 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
KLF5 Q13887 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
LMNA P02545 2/20 0.31
HTT P42858 2/20 0.31
ALDH1A1 P00352 2/20 0.31
KDM4E B2RXH2 1/20 0.31
GAA P10253 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
TSHR P16473 1/20 0.31
CASP1 P29466 1/20 0.31
HSD17B10 Q99714 1/20 0.31
CHRM4 P08173 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16472453 0.83 JAK1 (0.47) JAK2JAK1TYK2JAK3
SCHEMBL16472368 0.81 NPC1 (0.39) OGAPTGESNR1I2SMN1; SMN2NPC1
SCHEMBL18291300 0.81 IKBKB (0.36) OGAPTGESSMN1; SMN2NPC1RAB9A
SCHEMBL16472287 0.81 GPR119 (0.43) MAPT
SCHEMBL16472305 0.80 GPR119 (0.40) PTGESALDH1A1KDM4EMAPTTSHR
SCHEMBL16587752 0.77 OGA (0.38) OGAPTGESSMN1; SMN2NPC1RAB9A
SCHEMBL16472266 0.77 OGA (0.38) OGAPTGESSMN1; SMN2NPC1RAB9A
SCHEMBL16472278 0.75 GPR119 (0.44) PTGESMEN1KMT2AALDH1A1GAA
SCHEMBL16587773 0.72 GPR119 (0.39) OGAJAK2JAK1TYK2JAK3
SCHEMBL20249348 0.70 LCAT (0.36) PTGESSMN1; SMN2NPC1RAB9AKLF5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8987268-B2 Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases BRISTOL-MYERS SQUIBB COMPANY (US) 2015-03-24 US disclosed